Nektar Therapeutics-Product Pipeline Review-2015

Nektar Therapeutics-Product Pipeline Review-2015

  • Products Id :- GMDHC07250CDB
  • |
  • Pages: 70
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Nektar Therapeutics-Product Pipeline Review-2015


Global Markets Direct's, 'Nektar Therapeutics-Product Pipeline Review-2015', provides an overview of the Nektar Therapeutics's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nektar Therapeutics's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Nektar Therapeutics including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Nektar Therapeutics's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Nektar Therapeutics's pipeline products

Reasons To Buy

Evaluate Nektar Therapeutics's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Nektar Therapeutics in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Nektar Therapeutics's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Nektar Therapeutics and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nektar Therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Nektar Therapeutics and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Nektar Therapeutics Snapshot 7

Nektar Therapeutics Overview 7

Key Information 7

Key Facts 7

Nektar Therapeutics-Research and Development Overview 8

Key Therapeutic Areas 8

Nektar Therapeutics-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products-Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Nektar Therapeutics-Pipeline Products Glance 17

Nektar Therapeutics-Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

Nektar Therapeutics-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Nektar Therapeutics-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Nektar Therapeutics-Drug Profiles 22

etirinotecan pegol 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

NKTR-181 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

NKTR-171 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

NKTR-125 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

NKTR-140 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

NKTR-173 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NKTR-174 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

NKTR-192 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

NKTR-194 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

NKTR-195 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

NKTR-196 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

NKTR-214 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

NKTR-218 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

NKTR-223 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

NKTR-228 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

NKTR-230 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

NKTR-255 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Proteins for Hematological Disorders 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Drug to Inhibit Kinase for Cancer 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Protein for Oncology 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Protein to Agonize Cytokine Receptor for Inflammation 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Protein to Agonize Cytokine Receptor for Viral Infections 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecule to Antagonize NMDA Receptor for Pain and Depression 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecule to Inhibit Folate for Oncology 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Nektar Therapeutics-Pipeline Analysis 49

Nektar Therapeutics-Pipeline Products by Target 49

Nektar Therapeutics-Pipeline Products by Route of Administration 50

Nektar Therapeutics-Pipeline Products by Molecule Type 51

Nektar Therapeutics-Pipeline Products by Mechanism of Action 52

Nektar Therapeutics-Recent Pipeline Updates 53

Nektar Therapeutics-Dormant Projects 61

Nektar Therapeutics-Discontinued Pipeline Products 62

Discontinued Pipeline Product Profiles 62

NKTR-105 62

NKTR-192 62

Nektar Therapeutics-Company Statement 63

Nektar Therapeutics-Locations And Subsidiaries 68

Head Office 68

Other Locations & Subsidiaries 68

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

Nektar Therapeutics, Key Information 7

Nektar Therapeutics, Key Facts 7

Nektar Therapeutics-Pipeline by Indication, 2015 9

Nektar Therapeutics-Pipeline by Stage of Development, 2015 11

Nektar Therapeutics-Monotherapy Products in Pipeline, 2015 12

Nektar Therapeutics-Partnered Products in Pipeline, 2015 13

Nektar Therapeutics-Partnered Products/ Combination Treatment Modalities, 2015 14

Nektar Therapeutics-Out-Licensed Products in Pipeline, 2015 15

Nektar Therapeutics-Out-Licensed Products/ Combination Treatment Modalities, 2015 16

Nektar Therapeutics-Phase III, 2015 17

Nektar Therapeutics-Phase II, 2015 18

Nektar Therapeutics-Phase I, 2015 19

Nektar Therapeutics-Preclinical, 2015 20

Nektar Therapeutics-Discovery, 2015 21

Nektar Therapeutics-Pipeline by Target, 2015 49

Nektar Therapeutics-Pipeline by Route of Administration, 2015 50

Nektar Therapeutics-Pipeline by Molecule Type, 2015 51

Nektar Therapeutics-Pipeline Products by Mechanism of Action, 2015 52

Nektar Therapeutics-Recent Pipeline Updates, 2015 53

Nektar Therapeutics-Dormant Developmental Projects,2015 61

Nektar Therapeutics-Discontinued Pipeline Products, 2015 62

Nektar Therapeutics, Other Locations 68

Nektar Therapeutics, Subsidiaries 68

List of Figures

Nektar Therapeutics-Pipeline by Top 10 Indication, 2015 9

Nektar Therapeutics-Pipeline by Stage of Development, 2015 11

Nektar Therapeutics-Monotherapy Products in Pipeline, 2015 12

Nektar Therapeutics-Partnered Products in Pipeline, 2015 13

Nektar Therapeutics-Out-Licensed Products in Pipeline, 2015 15

Nektar Therapeutics-Pipeline by Top 10 Target, 2015 49

Nektar Therapeutics-Pipeline by Top 10 Route of Administration, 2015 50

Nektar Therapeutics-Pipeline by Top 10 Molecule Type, 2015 51

Nektar Therapeutics-Pipeline Products by Top 10 Mechanism of Action, 2015 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Nektar Therapeutics; Nektar Therapeutics - Key Therapeutics; Nektar Therapeutics - Pipeline Overview and Promising Molecules; Nektar Therapeutics - News; Nektar Therapeutics - Latest Updates; Nektar Therapeutics - Pipeline; Nektar Therapeutics - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102105
Site License
USD 3000 INR 204210
Corporate User License
USD 4500 INR 306315



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]